机构地区:[1]上海市第一人民医院检验科,上海虹口200080
出 处:《检验医学》2024年第7期673-681,共9页Laboratory Medicine
基 金:科技部国家重点研发计划项目(2022YFC2009600);上海市第一人民医院临床研究创新团队项目(CTCCR-2019D04)。
摘 要:目的分析核心结合因子(CBF)相关急性髓系白血病(AML)患者的年龄、性别等一般临床特征和相关实验室检测结果与疗效、复发和生存时间等预后因素的相关性,以期为临床优化治疗方案提供参考。方法选取2014年1月—2021年12月上海市第一人民医院使用标准诱导和巩固化疗方案的CBF-AML患者116例,其中77例接受了异基因造血干细胞移植(allo-HSCT)。根据融合基因分为伴RUNX1::RUNX1T1(第1组)AML和伴CBFB::MYH11(第2组)AML,采用Kaplan-Meier生存曲线分析2个组预后的差异。采用Cox回归分析评价预后影响因素。结果第1组和第2组基线特征[发病年龄、外周血白细胞计数和血红蛋白含量、骨髓原始细胞比例、额外染色体异常发生率、性染色体丢失、KRAS突变、NRAS突变]差异有统计学意义(P<0.05)。复发患者总生存期(OS)低于未复发患者(P=0.008)。男性、TET2突变和del(9q)的患者OS较短(P<0.05)。血小板计数<20×10~9·L-1的患者OS和无复发生存时间(RFS)均较短(P<0.05)。移植后复发患者的OS显著短于移植后未复发患者(P=0.001)。多因素Cox回归分析结果显示,复发、TET2突变和染色体del(9q)是CBF-AML患者OS缩短的显著危险因素(P<0.05),达到缓解天数是AML伴RUNX1::RUNX1T1患者OS的独立影响因素(P=0.038),骨髓原始细胞比例是AML伴CBFB::MYH11患者OS的独立影响因素(P=0.044)。结论CBF-AML患者2种融合基因亚组间在基线特征方面具有明显的异质性,TET2突变和del(9q)可显著影响患者生存天数,建议复发患者及时进行挽救性移植。应关注AML伴RUNX1::RUNX1T1患者达到缓解的天数,关注CBFB::MYH11患者原始细胞比例。Objective To analyze the correlation of general clinical characteristics(age and gender),laboratory determination results with prognosis(efficacy,recurrence and survival time)in patients with core binding factor(CBF)-related acute myeloid leukemia(AML),and to provide a reference for optimizing clinical treatment plans.Methods A total of 116 CBF-AML patients who received standard induction and consolidation chemotherapy at Shanghai General Hospital from January 2014 to December 2021 were enrolled,including 77 cases who received allogeneic hematopoietic stem cell transplantation(allo-HSCT).According to fusion genes,the subjects were classified into AML RUNX1::RUNX1T1(Group 1)and AML CBFB::MYH11(Group 2).Kaplan-Meier survival analysis and Cox regression analysis were used to evaluate the prognostic factors.Results There was statistical significance in baseline characteristics between Group 1 and Group 2,including age at onset,peripheral blood white blood cell count,hemoglobin level,bone marrow blast percentage,incidence of additional chromosomal abnormalities,sex chromosome deletion,KRAS mutation and NRAS mutation(P<0.05).The overall survival(OS)of patients with recurrence was lower than that of those without recurrence(P=0.008).Male,recurrence,TET2 mutation and del(9q)were related with poor OS(P<0.05).Patients with platelet count<20×109·L-1 had poor OS and relapse-free survival(RFS)(P<0.05).The OS of patients who recurred after transplantation was worse than that of patients who did not recurr after transplantation(P=0.001).Cox regression analysis showed that recurrence,TET2 mutation and chromosome del(9q)were risk factors for OS,and time to remission(days)was an independent influencing factor for OS in AML patients with RUNX1::RUNX1T1(P=0.038).The proportion of bone marrow blast percentage was an independent influencing factor for OS in AML patients with CBFB::MYH11(P=0.044).Conclusions There is heterogeneity in baseline characteristics between the 2 fusion genes of CBF-AML patients.TET2 mutation and del(9q)sign
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...